Plasmablastic Lymphoma — Trials

Plasmablastic Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

18 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 12
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 8%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04139304	A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma	recruiting	Early Phase 1	15	AIDS Malignancy ConsortiumNETWORK	1	Jun 1, 2026	clinicaltrials

Data updated 22 days agoSource updated Jun 1, 2026source: clinicaltrials